So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes ...

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary review to be potentially included in China's basic medical insurance drug ...

Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing hopes of the company entering the obesity space in the near term. A trial ...

Pfizer (PFE) closed the most recent trading day at $24.48, moving +1.28% from the previous trading session. The stock's ...

BEIJING, June 29 (Reuters) - Pfizer's GLP-1 drug Ecnoglutide and Innovent Biologics' mazdutide injection have passed a ...

Pfizer (NYSE:PFE) has announced a new CFO transition as Dave Denton prepares to step down in August, adding another management change at a time when the drugmaker is still working to rebuild growth ...

Pfizer stock (NYSE: PFE) currently trades at $29 per share, 45% below its peak level of $54 seen in December 2021. In contrast, Merck stock is up 54% over this period. PFE stock was trading at $47 in ...

Pfizer’s top cancer drugs are small molecules, but dealmaking has expanded the pharmaceutical giant’s portfolio and pipeline with biologic medicines. Its latest deal puts it in a camp of companies ...

Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The stock is currently trading near $26.84 but remains well below its 52-week high ...